Cinfa Group

Cinfa is part of Infarco, a parent company for several firms that handle different business lines in the world of health, and which have gradually been formed to make what is now Cinfa Group.

The Group currently has more than 2,200 employees and is undergoing a process of international diversification and expansion with participation in companies of different countries.


Other companies in Cinfa Group

Orliman, leader in orthopaedics

For 30 years Orliman has been  investigating, developing, manufacturing and selling products to prevent injuries, for rehabilitation and for treating chronic problems related to mobility.

A European point of reference for orthopaedic solutions, it holds a solid position in France and Spain.

Natural Santé, developer of nutritional supplements

Created in 1986 and with a major presence in the French market, Natural Santé is a company that specialises in the development and marketing of nutritional supplements, medical devices and products based on medicinal plants.

It currently has three leading brands corresponding to its different business lines and it ranks among the ten leading companies in the French pharmaceutical  market for nutritional supplements.

Santé Verte:

Plantes Laboratoire:

Diet Horizon:

Sakura Italia, specialist in healthcare

An Italian firm that commenced in 2004, Sakura has an extensive portfolio of innovative healthcare products and nutritional supplements that it markets in over 24 countries in Europe, Asia and the Middle East.

Its range of healthcare products includes almost 40 products geared towards six therapeutic areas: gynaecology, the immune system, circulation, digestion, respiratory medicine and skin care.

Cyndea Pharma, specialist in hormonal therapies

Cyndea Pharma is a pharmaceutical laboratory located in Ólvega (Soria), leader in the manufacture of hormonal therapies.

Cyndea Pharma currently develops and manufactures steroid-based medications and oncology treatment for hormone-dependent tumours (e.g. breast cancer, endometrial cancer, uterine cancer or prostate cancer). And it makes use of specific technology for manufacturing soft gelatine capsules.